John Sullivan, a member of Cozen O’Connor’s Commercial Litigation Department, discusses Amarin’s successful motion for a preliminary injunction in its First Amendment challenge to the FDA’s regulation of off-label marketing and discusses what this means for the FDA.
To read the article, click here.